VRTX

Boston, Massachusetts-based Vertex Pharmaceuticals Incorporated (VRTX) develops and commercializes therapies for treating cystic fibrosis (CF). Valued at $123.2 billion by market cap, the company invests in scientific innovation to create transformative medicines for people with serious diseases. The biotechnology company is expected to announce its fiscal second-quarter earnings for 2026 after the market closes on Monday, Aug. 3. Ahead of the event, analysts expect VRTX to report a profit of $4.25 per share on a diluted basis, up 6.3% from $4 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports. Dear Google Stock Fans, Mark Your Calendars for July 13 Taiwan Just Waved a Red Flag for Nvidia Stock Taiwan Semi Stock Is Approaching Fair Value Ahead of July 16. How to Play TSM Here. Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. For the full year, analysts expect VRTX to report EPS of $17.07, up 3.6% from $16.47 in fiscal 2025. Its EPS is expected to rise 11.1% year over year to $18.97 in fiscal 2027. VRTX stock has underperformed the S&P 500 Index’s ($SPX) 20.6% gains over the past 52 weeks, with shares up 1.2% during this period. Similarly, it underperformed the State Street Health Care Select Sector SPDR ETF’s (XLV) 18% returns over the same time frame. On May 4, VRTX shares closed up more than 1% after reporting its Q1 results. Its adjusted EPS of $4.47 surpassed Wall Street expectations of $4.23. The company’s revenue was $2.99 billion, beating Wall Street forecasts of $2.98 billion. VRTX expects full-year revenue in the range of $13 billion to $13.1 billion. Analysts’ consensus opinion on VRTX stock is bullish, with a “Strong Buy” rating overall. Out of 33 analysts covering the stock, 24 advise a “Strong Buy” rating, two suggest a “Moderate Buy,” six give a “Hold,” and one recommends a “Strong Sell.” VRTX’s average analyst price target is $550.79, indicating a potential upside of 13.5% from the current levels. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com

BOSTON, July 07, 2026--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2026 financial results on Monday, August 3, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Second Quarter 2026 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 16 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and X. (VRTX-WEB) Source: Vertex Pharmaceuticals Incorporated View source version on businesswire.com: https://www.businesswire.com/news/home/20260707456160/en/ Contacts Vertex Pharmaceuticals...

Vertex Pharmaceuticals (VRTX) presented phase 3 data showing Casgevy delivered durable benefits in c

It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD). Shares have lost about 3.7% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Acadia due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Acadiareported first-quarter 2026 earnings per share (EPS) of 2 cents, which missed the Zacks Consensus Estimate of 4 cents. In the year-ago quarter, the company had reported EPS of 11 cents. In the first quarter, Acadia recorded total revenues of $268.1 million, which missed the Zacks Consensus Estimate of $282 million. ACAD’s net product revenues comprise sales of its two marketed products, Nuplazid (pimavanserin) and Daybue (trofinetide). Total revenues increased 10% year over year, driven by contributions from Daybue and continued growth in Nuplazid's market share. Revenues from Nuplazid increased 5% year over year to $167 million in the first quarter of 2026, driven primarily by volume growth. Nuplazid sales missed the Zacks Consensus Estimate of $179.7 million. Daybue recorded net product sales of $101 million in the reported quarter, up 20% year over year, driven by the growth in the drug’s unit sales as Acadia shipped to more unique patients. The reported figure, however, missed the Zacks Consensus Estimate of $105.6 million. Research and development (R&D) expenses were $76.9 million, down 2% year over year. Selling, general and administrative (SG&A) expenses were $171 million, up 35% year over year, due to increased marketing investments to support the continued growth of Nuplazid and Daybue. Acadia had cash, cash equivalents and investments worth $851 million as of March 31, 2026, compared with $820 million as of Dec. 31, 2025. Acadia continues to expect total revenues from the U.S. sales of its products to be in the range of $1.22-$1.28 billion in 2026. Nuplazid net product sales are expected to be in the range of $760-$790 million, while U.S. sales of Daybue are expected to be between $460 million and $490 million. R&D expenses in 2026 are projected to be in the range of $385-$410 million, while SG&A expenses are expected to be between $660 million...

It has been about a month since the last earnings report for Jazz Pharmaceuticals (JAZZ). Shares have added about 1% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Jazz due for a pullback? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent catalysts for Jazz Pharmaceuticals PLC before we dive into how investors and analysts have reacted as of late. Jazz Pharmaceuticals reported first-quarter 2026 adjusted earnings per share (EPS) of $6.34, which beat the Zacks Consensus Estimate of $4.67. In the year-ago quarter, the company posted EPS of $1.68, which was significantly impacted by higher operating expenses. Total revenues rose 19% year over year to $1.07 billion, which beat the Zacks Consensus Estimate of $972 million. Net product sales increased 22% year over year to $1.03 billion. The reported figure beat both the Zacks Consensus Estimate of $925 million and our model estimate of $924 million. Jazz recorded about $36.3 million in royalty revenues from high-sodium oxybate authorized generic (AG), down about 26% year over year. Other royalties and contract revenues declined 23% to $7.3 million. Net product sales for the combined oxybate business (Xyrem + Xywav) rose 15% to $439.4 million. This combined figure beat both the Zacks Consensus Estimate of $390 million and our model estimates of $393 million. Sales of Xyrem declined 16% year over year to $31.2 million due to patients switching to Xywav and the launch of AGs in 2023. Xywav recorded sales of $408.2 million in the quarter, up 18%. This upside can be attributed to the encouraging uptake of the drug in narcolepsy and IH indications. This drug is currently Jazz’s most extensive product by net sales. Sales of Epidiolex/Epidyolex rose 15% to $249.8 million, driven by continued strong demand. This metric also beat the Zacks Consensus Estimate of $238 million and our model estimate of $234 million. Oncology product sales rose 45% to $333.4 million. Rylaze/Enrylaze posted sales of $103.7 million, up 10% year over year. This figure beat the Zacks Consensus Estimate and our model estimate, each pegged at $97 million. Zepzelca recorded sales of $101 million, up 60% year over year. This upside was primarily driven by continued uptake of the drug in the recentl...

It has been about a month since the last earnings report for Vertex Pharmaceuticals (VRTX). Shares have added about 0.2% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Vertex due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Vertex Pharmaceuticals Incorporated before we dive into how investors and analysts have reacted as of late. Vertex’s reported adjusted earnings of $4.47 per share for the first quarter of 2026, beating the Zacks Consensus Estimate of $4.23. Earnings rose around 10.1% year over year on higher product revenues, partially offset by higher operating expenses.First-quarter total revenues of $2.99 billion slightly beat the Zacks Consensus Estimate of $2.98 billion. Total revenues rose 8% year over year, primarily driven by higher sales of CF drugs and meaningful contributions from new non-CF products, Journavx and Casgevy. Its total revenues rose 7% year over year in the United States to $1.78 billion, driven by strong demand for CF drugs, higher realized net prices in CF and Casgevy and Journavx sales. Outside the U.S. market, sales increased 9% to $1.21 billion, driven by strong CF growth, contribution from Casgevy and a favorable impact from foreign exchange. The company currently markets four CF products — Trikafta/Kaftrio, Symdeko (marketed as Symkevi in Europe), Orkambi and Kalydeco.Trikafta generated sales worth $2.35 billion, down 7.5% year over year. The product’s sales missed the Zacks Consensus Estimate of $2.39 billion.Alyftrek generated sales worth $424.4 million in the first quarter compared with $380.1 million in the fourth quarter. Alyftrek sales beat the Zacks Consensus Estimate of $408 million. The drug has now surpassed $1 billion in cumulative global revenue since its approval.Vertex said that the U.S. and European launch of Alyftrek is progressing well. Outside the United States, the company signed reimbursement agreements for Alyftrek in 11 countries during the first quarter aloneRevenues from other CF products (including Kalydeco, Orkambi, and Symdeko/Symkevi) decreased 12.5% year over year to $135.9 million. Vertex expects incremental patients from the label expansions for Alyftrek and Trikafta, along with launches of Alyftrek in add...

Vertex Pharmaceuticals' first quarter results reflected balanced growth across its cystic fibrosis franchise and newly launched therapies, with management highlighting commercial momentum in both established and emerging product areas. CEO Reshma Kewalramani pointed to "strong revenue growth as we reach more patients with more products," emphasizing milestone achievements for AlifTrack, KASJEVY, and Gernavix. The company also attributed performance to broader label eligibility and successful international expansion, particularly for its cystic fibrosis therapies. Management cited robust operational execution in research and development, including rapid regulatory submissions and advancement of late-stage clinical programs. Is now the time to buy VRTX? Find out in our full research report (it’s free). Revenue: $2.99 billion vs analyst estimates of $2.95 billion (7.8% year-on-year growth, 1.2% beat) Adjusted EPS: $4.47 vs analyst estimates of $4.31 (3.8% beat) Adjusted EBITDA: $1.37 billion vs analyst estimates of $1.33 billion (45.7% margin, 2.5% beat) The company reconfirmed its revenue guidance for the full year of $13.03 billion at the midpoint Operating Margin: 38.1%, up from 22.7% in the same quarter last year Market Capitalization: $109.1 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Jessica Fye (JPMorgan): asked about the potential for the renal franchise to rival cystic fibrosis in size. CEO Reshma Kewalramani detailed the significant patient populations for Vertex’s renal assets and highlighted Povi as the near-term focus due to strong clinical data. Salveen Richter (Goldman Sachs): inquired about data read-through from a competitor’s program to Vertex’s enaxaplin. Kewalramani emphasized Vertex’s trial design and noted that results from the separate AMPLIFIED study are expected later this year. Brian Abrahams (RBC Capital Markets): questioned how Vertex would differentiate Povi for physicians given existing competition. Chief Commercial Officer Duncan McKechnie stressed Povi’s unique clinical profile, monthly dosing, and supportive infrastructure for rapid reimbursement and patient access. David Ri...

Vertex Pharmaceuticals Incorporated’s VRTX first-quarter 2026 results were decent as it beat estimates for earnings and sales. The company’s total revenues of $2.99 billion rose 8% year over year, driven by higher sales of cystic fibrosis (CF) drugs Trikafta/Kaftrio and Alyftrek, as well as meaningful contributions from new non-CF products, Journavx and Casgevy. Vertex reiterated its full-year 2026 revenue guidance in the range of $12.95-$13.10 billion for 2026. Investor focus was on the performance of Vertex’s newer drugs, Alyftrek, Journavx and Casgevy, which were launched in the past couple of years and hold the key to long-term growth. Alyftrek is a once-a-day oral triple combination regimen for CF. Journavx is a novel non-opioid pain medicine (suzetrigine) and Vertex and partner CRISPR Therapeutics’ CRSP Casgevy is a one-shot gene therapy approved for two blood disorders, sickle cell disease and transfusion-dependent beta-thalassemia. Year to date, shares of Vertex have declined 6.3% compared with the industry’s decrease of 0.2%. Image Source: Zacks Investment Research Let’s dig deeper to understand how these new products performed in the first quarter and the company’s outlook for the same through the rest of the year. Alyftrek continues to outperform expectations and generated sales worth $424.4 million in the first quarter compared with $380.1 million in the fourth quarter. The rollout of Alyftrek in the United States and Europe is progressing well across all patient groups. The drug has now surpassed $1 billion in cumulative global revenues since its approval in the United States in late 2024 and in the EU in July 2025. Alyftrek’s once-daily dosing and improved sweat chloride profile continue to resonate with patients and doctors. In the first quarter, products from Vertex’s new non-CF disease areas, namely Casgevy and Journavx, drove approximately 25% of total product revenue growth, which was encouraging as Vertex’s dependence on just the CF franchise for revenues has been a growing concern. CF sales are also slightly slowing down. Journavx (suzetrigine) generated $29 million in sales in the first quarter compared with $26.7 million in the fourth quarter. Prescription growth remains strong, although first-quarter revenues reflected some normal inventory destocking. More than 350,000 prescriptions were written for Journavx across both hospital and...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) came out with its first-quarter results last week, and we wanted to see how the business is performing and what industry forecasters think of the company following this report. The result was positive overall - although revenues of US$3.0b were in line with what the analysts predicted, Vertex Pharmaceuticals surprised by delivering a statutory profit of US$4.02 per share, modestly greater than expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Vertex Pharmaceuticals after the latest results. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Taking into account the latest results, the current consensus from Vertex Pharmaceuticals' 29 analysts is for revenues of US$13.0b in 2026. This would reflect a modest 6.7% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to rise 2.1% to US$17.46. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$13.0b and earnings per share (EPS) of US$17.45 in 2026. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates. View our latest analysis for Vertex Pharmaceuticals It will come as no surprise then, to learn that the consensus price target is largely unchanged at US$550. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. Currently, the most bullish analyst values Vertex Pharmaceuticals at US$641 per share, while the most bearish prices it at US$330. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable. Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We would...

Vertex Pharmaceuticals VRTX reported adjusted earnings of $4.47 per share for the first quarter of 2026, beating the Zacks Consensus Estimate of $4.23. Earnings rose around 10.1% year over year on higher product revenues. First-quarter total revenues of $2.99 billion slightly beat the Zacks Consensus Estimate of $2.98 billion. Total revenues rose 8% year over year, primarily driven by higher sales of cystic fibrosis (CF) drugs Trikafta/Kaftrio and Alyftrek, as well as meaningful contributions from other new products, Journavx and Casgevy. Year to date, shares of Vertex have declined 5.2% compared with the industry’s decrease of 3.2%. Image Source: Zacks Investment Research Trikafta generated sales worth $2.35 billion, down 7.5% year over year. The product’s sales missed the Zacks Consensus Estimate of $2.39 billion. Alyftrek, a next-in-class triple combination regimen for CF, generated sales worth $424.4 million in the first quarter compared with $380.1 million in the fourth quarter. Per management, the U.S. and European launch of Alyftrek is progressing well across all patient groups. The drug has now surpassed $1 billion in cumulative global revenue since its approval. Revenues from other CF products decreased 12.5% year over year to $135.9 million. Revenues from Vertex and partner CRISPR Therapeutics’ CRSP one-shot gene therapy, Casgevy, were $42.9 million in the first quarter of 2026, down from $54.3 million recorded in the fourth quarter of 2025. Casgevy is approved for two blood disorders, sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). Vertex leads the global development and commercialization of Casgevy under the terms of the 2021 agreement, with support from CRISPR Therapeutics. Vertex’s newest pain drug, Journavx (suzetrigine) generated $29 million in sales in the first quarter compared with $26.7 million in the fourth quarter. Journavx, a novel non-opioid pain medicine (suzetrigine), was approved in the United States in January 2025. Adjusted research and development (R&D) expenses declined 2.2% year over year to $859.3 million. Adjusted selling, general and administrative (SG&A) expenses rose 29.8% to $432.2 million in the reported quarter, primarily to support the launch of Journavx. During the quarter, Vertex recorded acquired in-process research and development (AIPR&D) costs of $0.5 million compared with $19.8 milli...

Vertex stock skidded Tuesday on a mixed first-quarter report, but analysts remain more interested in the company's R&D plans.

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.47 per share, beating the Zacks Consensus Estimate of $4.23 per share. This compares to earnings of $4.06 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +5.76%. A quarter ago, it was expected that this drugmaker would post earnings of $5.07 per share when it actually produced earnings of $5.03, delivering a surprise of -0.79%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Vertex, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $2.99 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 0.19%. This compares to year-ago revenues of $2.77 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Vertex shares have lost about 6.5% since the beginning of the year versus the S&P 500's gain of 5.6%. While Vertex has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Vertex was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy...